| Autor: |
Cai, Rui, Decuypere, Flore, Chevalier, Pierre, Desseilles, Martin, Lambert, Martin, Fakra, Eric, Wimmer, Antonie, Guillon, Pascal, Pype, Stefan, Godet, Annabelle, Borgmeier, Valeria |
| Rok vydání: |
2022 |
| DOI: |
10.6084/m9.figshare.20023181 |
| Popis: |
Additional file 1: FigureS1. Sensitivity analysis: treatmentdiscontinuation by product – patients newly initiated on paliperidone palmitateor risperidone microspheres (using a grace period of 120 days). FigureS2. Treatment discontinuation by product and percountry – patients newly initiated on paliperidone palmitate and risperidonemicrospheres. Figure S3. Treatment discontinuation by gender and per country – patientsnewly initiated on paliperidone palmitate and risperidone microspheres. FigureS4. Treatment discontinuation by previoustreatment and per country – patients newly initiated on paliperidone palmitateand risperidone microspheres. FigureS5. Treatment discontinuation by 30-day averagedose and per country – patients newly initiated on paliperidone palmitate andrisperidone microspheres. FigureS6. Treatment discontinuation by mono- andcombination therapy and per country – patients newly initiated on paliperidonepalmitate and risperidone microspheres. FigureS7. Treatment discontinuation by prescribers’specialty and per country – patients newly initiated on paliperidone palmitateand risperidone microspheres. FigureS8. Treatment discontinuation by age and percountry – patients newly initiated on paliperidone palmitate and risperidonemicrospheres. FigureS9. Sensitivity analysis: treatmentdiscontinuation by product – stable PP3M patients vs. stable PP1M patients (graceperiod: 120 days). Table S1. Patient characteristics of stable patients with PP1M and PP3M. Table S2.Univariate and multivariate Cox regression analysis of treatment discontinuationof patients with PP1M and PP3M. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
